Helus Pharma (HELP) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$2.01
- Estimate
- -$1.01
- Surprise
- -99.0%
- Score today
- 4.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Helus Pharma (HELP) reported a wider loss than forecast — adjusted EPS of -$2.01 against the -$1.01 estimate (a 99.0% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates HELP Sell at 4.6/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -99.0% surprise compares with a -32.1% four-quarter average.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $40.63 vs price $8.87 — ratio 4.6×). Rejected, falling back to technical TP.
- Quality below floor (1.2 < 4.0)
- EARNINGS_PROXIMITY:1d<=7d
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.87
- Price target
- $11.51
- Stop
- $8.25
- Upside to target
- +29.8%
Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.
HELP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $648.1M
- P/E (fwd)
- -5.0
- 52-week range
- $3.76–$15.15
- Off 52-week high
- 41.5%
- RSI (14)
- 37
- Volume vs avg
- 0.69×
- Score today
- 4.6/10